Great. Thank you very much. We're going to have some fun without Akash here. You will have to tell him that we did a good job running the session without him. I just thought I would just share just a few slides before we get into the Q&A that will also give Akash a bit of time to get over here. It is three years now, 1st of December, since I joined BioMarin. We have made a lot of changes, so I am very excited about where the company is right now. These slides will, I think, give you a good perspective of where we are. Obviously, I am going to be making forward-looking statements. For those of you that do not know BioMarin, we are a global rare disease leader at scale.
He made it.
Hey, there, Akash.
I made it.
That's quite an entrance. Is there anything you want to say, or shall I just keep going?
No, yeah, I almost got hit by a cab, but that's it. But yes, please go ahead.
Good, good.
No, please start with intro remarks.
Okay. Good, good. We are in 80 countries. Next year will be our 30th anniversary. We now have nine approved products. Five of them are in the metabolic condition space. Six of them are first- in- disease treatments. This year, at the midpoint of our guidance of $3.8 billion-$3.9 billion, we will be at 20% growth. Out of those nine products, four of them, we believe, have the potential to be over a billion-dollar products. This is all built on a base of capabilities and global reach, which allows us, we believe, to continue to create enormous amounts of value for patients and for investors. We have global capabilities end-to-end, from research, development, regulatory, manufacturing, and obviously commercialization in that global footprint. We are really experts at rare disease and finding patients and getting them started on the therapy and keeping them successfully on therapy and getting the benefits.
I am now going to hand over to Brian to go through just two slides on financial performance.
Thanks, Alexander. BioMarin's efforts to strengthen our financial profile over the last couple years are showing up in our results. Using the midpoint of the 2026 revenue guidance, revenue is on track to grow approximately 60% over the last three years. Earnings per share has doubled. The middle panel here stops at 2025. I will share that for 2026. There are a couple of acquisition-related in-process R&D charges coming through the financials, so we did not show 2026 here. But if you look through those, our operational earnings per share over the three-year period is also on track to more than double. That profitability is translating to cash flow, where our operating cash flow has increased by more than 5 x from 2023 to 2025.
It is that strengthened cash flow performance that helped fund the Amicus acquisition earlier this year, which brought two rare disease medicines, GALAFOLD for Fabry disease and POMBILITI and OPFOLDA for Pompe disease, into our portfolio. The transaction closed in April, so Q3 was just our first quarter of the combined company results, and we showed that we can continue to add more patients to both of these therapies in BioMarin's hands. This acquisition was highly synergistic. We have identified approximately more than 50% of the non-GAAP operating costs as synergies in the combined business. This integration is operationally on track. We have already pulled forward two of our deleveraging and accretion metrics since closing the transaction earlier this year. Our views of peak revenue for GALAFOLD and POMBILITI and OPFOLDA are $1.4 billion and $1.2 billion, respectively.
This is approximately a 40% and 20%, respectively, uplift on what some of the prior views of peak were, again, delivering upon the strategic rationale of this transaction. With the synergies, we expect that by the end of this decade, running the Amicus business on the BioMarin platform can generate operating margins of approximately 60%. That cash flow is enabling us to reinvest in the business. I refer to this sometimes as a virtuous cycle, where we believe we can both grow revenue and profitability and simultaneously invest in innovation. I think we're showing that with some of the new additions to our pipeline this year. I'll hand it back to Alexander for that.
Thanks, Brian. Yeah, so let me pick up with your virtuous cycle, Brian. We're taking these at-scale global rare disease player, the capabilities we have here, together with that diversified growth profile and the financial strength that you just saw from Brian's presentation, and we're reinvesting it in growth. We brought four pipeline products into our company in the last 12 months. Here are the four products, and no doubt, Akash, you're going to ask me a lot of questions about each one of these. We got BMN 820 as part of the Amicus acquisition. This is for FSGS, a very interesting indication. It's a phase III asset. We expect the readout in 2028. BMN 333 is an internal asset. It's our long-acting CNP. We're designing this to be, we believe, have the potential to be best in class in achondroplasia and hypochondroplasia.
Importantly, it has phase II readout in patients in 2027. Obviously, you're very familiar with the market size, 24,000 patients globally. BMN 440, we got this as part of the Alesta acquisition. This will be the first oral treatment, we hope, in hypophosphatasia. So a very large, significant market, about 35,000 patients. This is a lot more than an oral therapy in a market that is an injectable market. By being an oral therapy, we believe it can be systemically absorbed and address many of the issues that are currently not addressed by the current enzyme therapies in this disease. Finally, we have BMN 450. This is our most recent acquisition, announced, what, two weeks ago now. This is potentially the first subcutaneous treatment for Fabry disease. Obviously, this is a market we're already now in with GALAFOLD in Fabry disease.
This allowed us to address a larger population, so not just the genetic amenable population. Again, this will be an important advance for patients as a subcutaneous therapy versus the injectable drugs. So, these are four very important pipeline drugs. Let's now talk about, with the final slide, as I say, many, many important catalysts in the coming period. So looking ahead to the remainder of this year and 2027 and into 2028. We have the pending FDA approval of VOXZOGO in hypochondroplasia. This will be, and we're very proud of these milestones, this will be our seventh first-in-disease treatment if we're approved. It's also in front of Europe, and we're potentially also launching it around the world in multiple countries next year. We have the phase II results of 333, the long-acting CNP.
We also have the first patient data for BMN 440, the drug I talked about, in hypophosphatasia. We've got a lot of very, very important milestones coming up and clinical catalysts, together with obviously the ongoing financial strength and growth of our underlying business. With that, Akash, over to you.
I appreciate it, and thanks so much for the intro remarks. You got into your tenure at BioMarin, and I think I could notice how thoughtful you were. You took time to really listen to what shareholders wanted. You assessed the company internally. You moved into kind of a business unit structure. I have to give you credit. I mean, if you look at the margin profile of the company, it's materially improved under your tenure. We haven't necessarily seen maybe the stock reflect the operational changes that you've incorporated. I think the question that I get as an analyst and I struggle with, and I'm sure you do as well, which is, what do I have to show you guys to give us credit for what we're building here?
So, kind of reverse engineer that problem, because I'm sure you have this discussion from a strategic perspective, with a board perspective. What have you heard from investors over the last couple years in your tenure about what we want out of BioMarin? What do you think you'd be able to show in 2027 to really start getting credit from a stock price perspective?
Yeah, absolutely. I mean, first and foremost, and I'm not just saying this, as a leadership team and a board, we're focused on things that we believe are driving fundamental long-term value creation. We've made a lot of changes, which I think unambiguously have created a lot of value. They have not yet been appreciatedâ
Yeah
âby the external market. I think quite clearly, and no doubt we're going to talk about this, it's the competitive overhang on VOXZOGO, where we have two competitors. One, as you well know, has launched about three quarters ago, and one is pending approval. I think that has been totally blown out of context in terms of its impact on BioMarin's future growth. If you look at VOXZOGO in achondroplasia, which is the indication currently under competition, in the United States, that's only 6% of our revenue. And we do not expect to lose that business. We will have the infant indication advantage for several more years, which is where the majority of patients started around the world. In addition, this plays into this 80-country global footprint that we talked about. 75% of our revenue with VOXZOGO is outside the United States.
This has been part of the theme. The other part of the theme has been, well, okay, we see the value that you're creating. We think, and I don't want to be immodest. Here I am in London, and I feel like I really shouldn't be immodest in London. It's the British part of me. But people say, "We like the decisions, the speed of the decisions. We like the execution. But why now? Why do we have to buy now? What are the catalysts?" And I think you can see now that we have taken this financial performance and built a really compelling pipeline of drugs, which are completely on strategy. These are, as you can see, really fit into our expertise in genetic conditions. They drop really right into, most of them drop right into those business units we set up of skeletal conditions and metabolic conditions.
And we're now in this situation where we've got these. We're a bit more like your classic U.S. biotech, where we have this pipeline optionality, which is important to U.S. investors. But we're marrying it together with a diversified, strong financial profile, which, gosh, here I am making friends and influencing people here, which many U.S. biotech companies don't have that strength of that financial performance, that level of profitability and cash flow that we have. So I think we are now really at the point of offering something for everybody, and I think that will start to resonate with folks.
Understood. It's been interesting. You look at companies like AbbVie or J&J, like they've had massive moves. I know that's a large-cap pharma, but you would hear investors and you would say, "This company has tremendous earnings visibility." And it's interesting, even if you look at some of the rotation into large-cap biotech now, the number one predictor of stock performance seems to be positive estimate earnings revisions going into next year. I feel like there is that potential for BioMarin, right? Whether it's stability on VOXZOGO, whether it's the Amicus integration and really how quickly that can get done. But that also gets into this kind of interesting question of, well, how do we get guidance right? So guide people towards what we're really excited about, the financial profile, but also make sure that we're able to deliver on that, if not more.
So what have we learned maybe from last year with some of the moving parts within the product portfolio? How de-risked is that as we get into next year? Again, what's the view of guidance for BioMarin under your tenure now?
Do you want to handle this, Brian?
I'll start, then you can bring it back up to a higher level. First of all, on execution, we've been executing, Akash. We've got, with the third quarter, 15 consecutive quarters of beating consensus on non-GAAP earnings per share, which is our primary operating measure. We also have a strong track record of delivering, if not over-delivering, on revenue. We adjusted our Q3 guidance because of timing of a basket of orders from a single large international market. The 80-country footprint that Alexander referred to is two-thirds outside of the U.S. Most of these BioMarin customers are single national payer healthcare systems, and they tend to order infrequently and sometimes with some volatility. Between Q2 and Q3, that customer shared with us that they wanted to defer some orders from planned in Q4 to early 2027.
That was just a mere timing shift, normal part of our business, but this late in the year, it was difficult to find the offsets. In terms of portfolio shifts, you might be referring to ROCTAVIAN. That was a challenging journey, but we think we made the right business decisions for both the value of the business going forward and the focus of the business to deliver value to shareholders. We think we've largely moved past that now, and now we're focusing on executing the strategy that you saw us summarize today.
Understood. Now, maybe going into your pipeline, I always find this a bit curious. BMN 333, I'm looking forward to. I think there's a shot that your team can show superiority, but look, it's preclinical data. The biology is TBD, and I think your team openly acknowledges that. But I feel like there's a faulty investor perception that, well, they're going for superiority, and if they can't get it for superiority, there's no way they can power a study for non-inferiority because it takes so many patients. Ergo, BMN 333 may not move forward. For me, I think, look, worst-case scenario, you have a weekly option. You're already in a leadership position in achondroplasia, and having more options for patients has never been the wrong thing. Can we address that directly?
Let's say that we get the phase II data next year, and we don't feel confident, your team, that you can show superiority. Does that mean that there isn't a path forward with BMN 333 in your product portfolio, or is that perception incorrect?
I'll answer the question in a couple of different ways. We are convinced that we've got the right drug to do this experiment. We also believe that the lane is open for a drug that offers superiority. There's nothing that so far has bested VOXZOGO from an efficacy standpoint, and actually from the evidence beyond height in terms of efficacy. So we think the lane is open. We think this is the right molecule. In the phase I healthy volunteer data, we far exceeded what we were hoping to see in terms of free CNP levels over and above what our competitor, the other long-acting CNP, has demonstrated. We've taken into the phase II three dosages that offered between three and eight times the level of free CNP than the competitor's long-acting drug.
But now the experiment needs to be done to say, does that PK translate through to additional growth? We think that we have a good reason to believe that's the case, but now we need to see the experiment. So we are designing, and we have designed, and we have FDA support for a seamless operational phase II, phase III design with a superiority endpoint, because that's what we believe the market really wants. That's what we believe will result in a best-in-class therapy, together with a longer dosing interval of a week. Now, we will look at that phase II data, and it won't just be the phase II data that comes out of the 40 patients in that study.
But using, really drawing upon the wealth of data we have from the VOXZOGO and the natural history studies, we will determine what the path forward is. Our plan A, plan B, plan C is superiority. We could look at those results and go, "You know what? We may go take a different path." If you are looking at a two-sided non-inferiority study, it is a large study, but we could do a one-sided non-inferiority study. I would not get ahead of ourselves. Our goal isâ
Right.
âsuperiority.
Understood. At least there is an option available. Okay, that makes sense. Now, going into your pipeline assets, to me, I always think with the question, well, when does this stock really work? I think, to your credit, Alexander, a lot of the BD you have done is going to be highly accretive because you have already built a commercial foothold in some of these markets, especially with your recent deal as a GALAFOLD add-on. Some of them are more even aspirational. I mean, hypophosphatasia, that is one of the biggest markets. Even Astra will talk about that. That might take some more time to really figure out. So, when you think about your pipeline, divide it up into two buckets. We feel very confident on the biology. We think this is scientifically de-risked.
Maybe not the biggest market opportunity, but it is highly synergistic to what we have. Here is our longer-term bets where it is aspirational, but man, if we are right, it is a home run, right? So, you talked about four assets. You have even more in your pipeline. If you were to put it through that lens, what is the low-hanging, de-risked fruit versus the aspirational bets for you?
Yeah. It is an interesting way of looking at it, and I would say, we have already talked about BMN 333. We know that space. As I say, we are using all of our experience and our expertise and our data to be able to really, I think, develop that program to the optimal level. I would probably say that BMN 450, which is, this is the subcutaneous treatment for Fabry disease, this is a space that we already have some level of expertise in, that we got as part of the Amicus acquisition. It is a subcutaneous treatment for Fabry, allows us to, again, address a larger population. I think that is pretty straightforward, and the data that we have already seen there gives us confidence that this looks like a really good drug. Then I think we have got BMN 440. Now, it is a large indication.
AstraZeneca talks about the potential for ALXN1850 as being between $3 billion-$5 billion. We're not in a situation here where we're going to be predicting what the potential could be, but I think the prospect of a small molecule, again, is really interesting. It clearly is much more than a patient convenience advantage, such as infigratinib versus VOXZOGO in achondroplasia. This potentially could allow us to address morbidity associated with hypophosphatasia in a way that both STRENSIQ and ALXN1850 is the follow-on molecule that AstraZeneca is developing, has not been able to address. On top of it, we think we have blue ocean, open water, whatever phrase you use, with the adult-onset population, where ALXN1850 had negative trial data.
Again, as an oral, where you can penetrate the muscle as opposed to bone penetrant, with an enzyme therapy, we think it gives us the potential to be able to maybe open up that indication. Now, probably it'll be a different study, because the endpoints will be different, but this is the work that we can do. We like to bring these programs in at this stage, because it gives us a chance to really shape the development program and invest at the level that these programs really require. The last one I'll mention is BMN 820, FSGS. I mean, it's a large indication. There's a significant unmet need there. We think this is a differentiated molecule, so it's a CCR2 inhibitor. It works in a different way than Travere's FILSPARI.
It potentially won't have the same restricted indication in terms of nephrotic status, and potentially not have the safety monitoring requirement. It's a very large disease, but I would say, this is one where we fully enrolled the study. We have the U.S. rights. We fully enrolled the study. We just have to wait now for the readout. It's a little harder to kind of assess what the likelihood of that is. This wasn't central to our thesis with buying Amicus. We could justify, as Brian alluded to, the Amicus acquisition purely on the GALAFOLD and POMBILITI opportunity on the revenue synergy side, the $1.4 billion and the $1.2 billion, together with the synergies on the expense side.
We got really BMN 820 as a bonus, and we think that's an interesting option, but we'll have to see what that readout looks like in 2028. I mean, the endpoint is de-risk at proteinuria.
Right.
We also are pleased to see that. We have a two-year proteinuria primary endpoint, and there is precedent for that to be approvable.
Understood. Last question, and this is more from a strategic perspective, and then also, again, investors may not get it. Counterparties might. Again, there used to be a debate about what the margin profile of BioMarin actually could be. You are now approaching earnings, margins, growth that would rival any kind of mid-cap commercial biotech, in some instances exceeded. That has always been kind of a common critique is, we do not know when this company will become profitable. I feel like you have answered that question. Investors do not get it. Do you feel like when you talk with strategics, when you talk with partners who are interested in tapping into your platform, that there is a growing appreciation of what you have built? Do you feel like there is a widening disconnect between investor perception and strategic perception of BioMarin right now?
I think we are in a very good situation, given the financial strength of the company and the profile and the capabilities that we have been able to build over 30 years, and to be in rare diseases and genetic conditions when, we do not have time to get into this, but genetic conditions with advanced analytics and AI, there is so much potential there. Also in an increasingly complex world with pharma political issues and pricing issues, rare disease is a really great space to be in. The strategics are not particularly focused on rare disease, and this is a great position for BioMarin to be in, as an at-scale leader in rare diseases. We are able to build our pipeline, leverage our capabilities.
We are not competing with the strategics for these assets, and we can now compete most of the smaller rare disease companies, given our scale and our financial resources. I do not think I should probably come to Jefferies and tell the strategics here, but they are focused on these highly prevalent populations, and I hope they leave us in rare disease to create an enormous amount of value for both patients and for investors.
Understood. Hey, thank you so much. I really do appreciate it.